Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P61278 (
somatostatin
)
22,083
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Here we characterize the intracellular effectors of the antiproliferative activity of
somatostatin
in glioma cell lines and post-surgical specimens. The responsiveness to
somatostatin
correlated with the expression of the phosphotyrosine phosphatase
DEP-1
/PTPeta, identified in C6 and U87MG cells, in which
somatostatin
inhibited cell growth. The expression of a dominant negative mutant of
DEP-1
/PTPeta in C6 cells abolished
somatostatin
effects, confirming the involvement of this phosphotyrosine phosphatase in such effects.
Somatostatin
treatment increased the activity of
DEP-1
/PTPeta and inhibited ERK1/2 activation. Conversely, basic fibroblast growth factor-dependent MEK phosphorylation was not affected, suggesting a direct effect on ERK1/2. In vitro experiments showed that PTPeta was able to interact and dephosphorylate ERK1/2 activated by basic fibroblast growth factor. Furthermore, by transfecting PTPeta in the
somatostatin
-unresponsive,
DEP-1
/PTPeta-deficient U373MG cells, the
somatostatin
-dependent control of cell proliferation was recovered. Finally we evaluated the requirement for
DEP-1
/PTPeta in
somatostatin
inhibition of cell proliferation in post-surgical specimens derived from different grade human gliomas. Although all of the glioma analyzed expressed somatostatin receptor mRNA,
DEP-1
/PTPeta expression was limited to 8 of 22 of the tumors. Culturing seven gliomas, a correlation between the expression of
DEP-1
/PTPeta and the
somatostatin
antiproliferative effects was identified. In conclusion we propose that the expression and activation of
DEP-1
/PTPeta is required for
somatostatin
inhibition of glioma proliferation.
...
PMID:The expression of the phosphotyrosine phosphatase DEP-1/PTPeta dictates the responsivity of glioma cells to somatostatin inhibition of cell proliferation. 1512 17
Activation of phosphotyrosine phosphatases (PTPs) by somatostatin receptor (SSTR) represents one of the main intracellular mechanisms involved in the antiproliferative effect of
somatostatin
(
SST
) and analogues. Since their molecular cloning, the role of PTPs is emerging as a major regulator of different cell functions including cell proliferation, differentiation, cell to cell interactions, cell matrix adhesion and cell migration. It was demonstrated that PTPs possess high substrate specificity and their activity is tightly regulated. Importantly, different G protein-coupled receptors transduce their biological activities through PTPs. PTPs were identified as down-stream effectors of SSTRs to transduce antiproliferative signals, and so far, three family members (SHP-1, SHP-2 and
DEP-1
/PTPeta) have been identified as selective SSTR intracellular effectors. Here, the molecular mechanisms leading SSTRs to regulate PTP activity are discussed, focusing on recent data showing a close interplay between PTPs and tyrosine kinases to transduce tumoral cell growth arrest following
SST
analogs administration.
...
PMID:Somatostatin/somatostatin receptor signalling: phosphotyrosine phosphatases. 1791 42